These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25594020)

  • 21. Downregulation of internal enhancer activity contributes to abnormally low immunoglobulin expression in the MedB-1 mediastinal B-cell lymphoma cell line.
    Ritz O; Leithäuser F; Hasel C; Brüderlein S; Ushmorov A; Möller P; Wirth T
    J Pathol; 2005 Feb; 205(3):336-48. PubMed ID: 15682441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary mediastinal B-cell lymphoma: a review of pathology and management.
    van Besien K; Kelta M; Bahaguna P
    J Clin Oncol; 2001 Mar; 19(6):1855-64. PubMed ID: 11251018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.
    Natoli A; Lüpertz R; Merz C; Müller WW; Köhler R; Krammer PH; Li-Weber M
    Int J Cancer; 2013 Oct; 133(8):1945-54. PubMed ID: 23553437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting STAT6 in PMBL.
    Leroy K; Pujals A; Pelletier L
    Oncotarget; 2014 Sep; 5(17):7216. PubMed ID: 25277174
    [No Abstract]   [Full Text] [Related]  

  • 27. The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma.
    Găman A; Bold A; Găman G
    Rom J Morphol Embryol; 2011; 52(2):719-22. PubMed ID: 21655667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma.
    Gentry M; Bodo J; Durkin L; Hsi ED
    Am J Surg Pathol; 2017 Feb; 41(2):189-194. PubMed ID: 27879516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
    Pytlík R; Belada D; Kubáčková K; Vášová I; Kozák T; Pirnos J; Bolomská I; Matuška M; Přibylová J; Campr V; Burešová L; Sýkorová A; Berková A; Klener P; Trněný M;
    Leuk Lymphoma; 2015 Jan; 56(1):57-64. PubMed ID: 24628294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.
    Pelland K; Mathews S; Kamath A; Cohen P; Hudnall SD; Cotta CV; Xu ML
    Appl Immunohistochem Mol Morphol; 2018; 26(10):e101-e106. PubMed ID: 29189264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
    Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
    Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of immunophenotypes and a nodular pattern in primary mediastinal large B-cell lymphoma.
    Maeshima AM; Taniguchi H; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Kobayashi Y; Tobinai K; Kushima R
    Pathol Int; 2014 Aug; 64(8):382-7. PubMed ID: 25143126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
    Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
    Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].
    Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic significance of pleural/pericardial effusion and treatment optimization of PMBL].
    Aoki T
    Rinsho Ketsueki; 2016 May; 57(5):575-84. PubMed ID: 27263781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Moore EM; Swerdlow SH; Gibson SE
    Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.